A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
about
Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's diseasePiribedil versus levodopa in early Parkinson's diseaseSide effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacologyNeuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine.Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives.Treatment of early Parkinson's disease.The initial treatment of Parkinson's disease should begin with levodopa.Treatment of Parkinson's disease should begin with a dopamine agonist.Pharmacological treatment of Parkinson's disease.Ropinirole in the treatment of Parkinson's disease.Dopamine agonists in the treatment of Parkinson's disease.Parkinson's disease management strategies.Effect of bromocriptine alginate nanocomposite (BANC) on a transgenic Drosophila model of Parkinson's disease.Drug treatment of Parkinson's diseaseRole of dopamine agonists in Parkinson's disease: an update.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Real Time Imaging of Biomarkers in the Parkinson's Brain Using Mini-Implantable Biosensors. II. Pharmaceutical Therapy with Bromocriptine.Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease.Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease.Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.Cabergoline versus levodopa monotherapy: a decision analysis.Bromocriptine use and the risk of valvular heart disease.The treatment of Parkinson's disease in older people.Therapeutic advances in idiopathic Parkinsonism.Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.Early (Uncomplicated) Parkinson's Disease
P2860
Q24242971-CD513814-D84A-4160-9BC3-17A35AEF5999Q24244961-2C75D710-7315-47A3-A09A-B49700A2AB8CQ26738349-A16506D8-DE8F-4EAE-94F7-B36CFBAC406AQ30394681-8759373E-C7E7-4832-87A2-F6FD9FF3161FQ33714121-7C336B34-C1E6-49A6-94DC-4F5A7881F400Q33714133-BBEBD216-A114-444A-8CA8-077998CEDA26Q33737387-9F1FCE01-557D-4E58-B33C-04E1F3F041D2Q33737392-613FE014-07B2-4ECF-BC44-1D28292A16C0Q34048261-DF0F1B9D-DF5A-4BE8-9F56-DBBD4D917B7BQ36181342-2252D3C8-2C36-4235-B993-A9DAF11B2CD4Q36390870-241A8C5F-8CE8-421A-B33C-2DD1A2B36372Q36390875-B3B678B7-5FF6-4456-857F-400396022057Q36506605-E4788A2B-170D-48DD-80E4-A91B4DAB0C87Q36902632-FFF8F056-0669-4446-8652-C8CAA4045C9DQ36972701-AB07D5D5-2266-4F98-BFE1-689922AE5BF3Q38070888-B577761F-949E-4A57-93BE-9BEF0062E106Q38262418-6CA9E0E6-7ABF-4CFC-8F31-0E0B8B68B308Q38645464-EE4DDEA3-5F3E-4FE9-A7F7-22F14CC3A1DDQ42692761-FAA1CDA9-D030-4FF8-96A7-65E11837090EQ43629634-0581C4B9-0FB1-4584-8975-F5E9B6833CC4Q44165230-3695DEB6-975E-4426-B7B5-DE04BCC18D05Q44531222-F29BDC35-BCA0-433C-88E0-7329D5801E8EQ46260213-CFC325A9-D223-4519-B7E2-1E7A13FE9108Q48338523-361F5298-AB00-40A8-A130-E0008BD8DD3BQ49115429-0EA635BA-692E-4ACC-9456-CC98E9AA5BE0Q53509756-C2B46981-2890-421D-B2BC-2581736F0EBCQ58870319-21D2590D-2C02-4F93-94B2-E4E8BB8C40A6
P2860
A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
description
1994 nî lūn-bûn
@nan
1994 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
A randomised controlled study ...... isease: a five year follow up.
@ast
A randomised controlled study ...... isease: a five year follow up.
@en
type
label
A randomised controlled study ...... isease: a five year follow up.
@ast
A randomised controlled study ...... isease: a five year follow up.
@en
prefLabel
A randomised controlled study ...... isease: a five year follow up.
@ast
A randomised controlled study ...... isease: a five year follow up.
@en
P2093
P2860
P356
P1476
A randomised controlled study ...... disease: a five year follow up
@en
P2093
J L Montastruc
P2860
P304
P356
10.1136/JNNP.57.9.1034
P407
P577
1994-09-01T00:00:00Z